Tipiracil is a pharmacological agent that inhibits the enzyme thymidine phosphorylase. Tipiracil is under research for combination effect with trifluridine in advanced or metastatic colorectal and gastric cancers. By inhibiting thymidine phosphorylase, Tipiracil enhances the bioavailability and efficacy of trifluridine, offering alternative in cancer research.